Scientific Programme

Tuesday 14th November 2023

Listed times are in Central European Time (CET)

11:30  REGISTRATION & WELCOME LUNCH (LUNCH FROM 12:00)

13:00  WELCOME TO DAY ONE

SESSION 1 - TECHNOLOGIES AND GENOMICS
Chair: Sophie Postel-Vinay

13:10  OPENING KEYNOTE LECTURE
Scott Lowe
Memorial Sloan Kettering Cancer Centre, New York, USA
"Understanding and exploiting tumor suppressive programs"
Q&A: 13:45-13:55

13:55  Céline Vallot
Institut Curie, Paris, France
"Mechanisms of cell plasticity in breast cancers"
Q&A: 14:15-14:25

14:25  Mirja Rotinen
Public University of Navarre, Pamplona, Spain
Proffered Paper 1: "ONECUT2 is a targetable lineage plasticity modulator of breast cancer that suppresses the estrogen axis"
Q&A: 14:35 - 14:40

14:40  EXHIBITOR INTRODUCTIONS

14:50  COFFEE BREAK & EXHIBITION

15:20  Jean Soulier
Hôpital Saint-Louis, INSERM, Paris, France
"Secondary leukemia to stressed hematopoiesis"
Q&A: 15:40-15:50

15:50  Renata Basto
Institut Curie, Paris, France
"Centrosome amplification induces apoptotic priming and favors the response to chemotherapy in epithelial ovarian cancer beyond multipolar divisions"
Q&A: 16:10-16:20

16:20  POSTER SPOTLIGHTS
Valeria Bica, University of Rome "Tor Vergata", Rome, Italy; Oriol de Barrios Barri, Josep Carreras Leukemia Research Centre, Barcelona, Spain; Naoyuki Nishiya, Iwate Medical University School of Pharmacy, Shiwa-gun, Japan
Wednesday 15th November 2023

Listed times are in Central European Time (CET)

08:30 EARLY POSTER VIEWING

SESSION 2: LEUKEMIA THERAPY
Chair: Patrick Mehlen

09:00 Andreas Trumpp
German Cancer Research Centre (DKFZ), Heidelberg, Germany
"MAC-scoring in leukemic stem cells predicts response to Venetoclax in AML patients"
Q&A: 09:20 - 09:30

09:30 Irina Korovina
HZDR – Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
Proffered Paper 2: "Integrin α2-deficiency reduces treatment resistance in glioblastoma by modulating ATF1 activity"
Q&A: 09:40 - 09:45

09:45 Hugues de Thé
College de France, Paris, France
"From nuclear architecture to leukemia cure: emerging roles of PML"
Q&A: 10:05-10:15

10:15 Yves Pommier
National Cancer Institute, Center for Cancer Research, Bethesda, MA, USA
"Genomics and Schlafen 11 (SLFN11) as predictors in oncology clinical trials"
Q&A: 10:35-10:45

10:45 COFFEE BREAK & EXHIBITION

11:15 Julien Ablain
CRCL, Lyon, France
"Investigating the mechanisms of melanoma development and therapy response using zebrafish"
Q&A: 11:35-11:45

11:45 Laura Broutier
CRCL, Lyon, France
Proffered Paper 3: "Modelling the next-generation of fusion-negative rhabdomyosarcoma 3D-organoids to predict effective drug combinations: a proof-of-concept on cell death inducers"
Q&A: 11:55 - 12:00

12:00 POSTER SPOTLIGHTS
Emmanuel Griessinger, Université Côte d’Azur, INSERM, Menton, France; Thi Nhat Uyen Nguyen, Taipei Medical University, Taipei, Taiwan; Sean Rudd,
Karolinska Institutet, Solna, Sweden

12:10  LUNCH & EXHIBITION

13:10  POSTER DISCUSSION SESSION 2

SESSION 3: NOVEL APPROACHES TO DRUG SENSITIVITY
Chair: Hugues de The

14:40  Sophie Postel-Vinay
IGR, Paris, France
"Harnessing genetic vulnerabilities in immuno-oncology: novel therapeutic opportunities"
Q&A: 15:00-15:10

15:10  Mattia Marinucci
University of Basel, Basel, Switzerland
Proffered Paper 4: "(Phospho)Proteomic analysis reveals vulnerabilities in metastatic colorectal cancer"
Q&A: 15:20 - 15:25

15:25  Hyunbin Huh
Yonsei, Seoul, South Korea
Proffered Paper 5: "Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination"
Q&A: 15:35 - 15:40

15:40  Patrick Mehlen
Lyon Cancer Research Center (CRCL), Paris, France
"Targeting netrin-1 in cancer: from mechanisms of cell death to patients"
Q&A: 16:00-16:10

16:10  COFFEE BREAK & EXHIBITION

16:40  Fanny Jaulin
Gustave Roussy, Villejuif, France
"Organoids as tools for functional precision medicine in advanced pancreatic cancer"
Q&A: 17:00-17:10

17:10  THE EMBO KEYNOTE LECTURE
Cedric Blanpain
Laboratory of Stem Cells and Cancer, ULB, Brussels, Belgium
"Targeting EMT mediated resistance to therapy"
Q&A: 17:30-17:40

17:40  PANEL DISCUSSION
Chair: Hugues de The
Sophie Postel-Vinay, IGR, Paris, France; Patrick Mehlen, CRCL, Paris, France; Fanny Jaulin (Gustave Roussy, Villejuif, France

19:30  CONFERENCE DINNER
The 3-course dinner will be at the Hotel Crowne Plaza Lyon’s restaurant, Antipasto. Optional ticketed event.

Thursday 16th November 2023
LISTED TIMES ARE IN CENTRAL EUROPEAN TIME (CET)

08:30 EARLY POSTER VIEWING

SESSION 4: METABOLISM AND SENESCENCE
Chair: Sophie Postel-Vinay

09:00 Filipe Cabriero
MRC London Institute of Medical Sciences, London, UK
"Microbially derived adjuvants for cancer chemotherapy"
Q&A: 09:20-09:30

09:30 Jean-Emmanuel Sarry
Centre de Recherches en Cancérologie de Toulouse (Oncopole), Toulouse, France
"Metabolic bases of drug resistance in acute myeloid leukemia"
Q&A: 09:50-10:00

10:00 Rocio Matesanz Sanchez
OncoRay – National Center for Radiation Research in Oncology, Dresden, Germany
Proffered Paper 6: "Targeting exostosin glycosyltransferase 2 (EXT2) modulates glioblastoma cell metabolism, sensitizing to X-ray irradiation via ferroptosis"
Q&A: 10:10 - 10:15

10:15 COFFEE BREAK & EXHIBITION

10:45 Geraldine Gentric
Institut Curie, Paris, France
"Role of stromal heterogeneity in resistance to treatments"
Q&A: 11:05-11:15

11:15 Closing Keynote - Clemens Schmitt
Max Delbruck Center, Berlin, Germany
"Apoptosis-competent anticancer treatment failure"
Q&A: 11:50-12:00

12:00 SUMMARY & CLOSE